HALOZYME THERAPEUTICS, INC.
HALO· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 46.2%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +39.2%
We record prices for the companies we cover; HALO is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 123.9M
- Revenue
- $1.4B
- Free cash flow
- $644.6M
- Owner earnings
- $593.0M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- 33.6%
- Net
- 22.7%
- Free cash flow
- 46.2%
- Owner earnings
- 42.5%
- Stock pay
- 3.7%
Returns
- ROIC, FY2025
- 15.5%
- ROIC, 5 yr avg
- –
- ROE, FY2025
- 649.2%
- ROE, 5 yr avg
- 286.1%
Growth (CAGR)
- Revenue, 3 yr
- 28.4%
- Revenue, 5 yr
- 39.2%
- Revenue, 9 yr
- 28.5%
- Diluted EPS, 3 yr
- 21.1%
- Diluted EPS, 5 yr
- 23.0%
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- 39.9%
- Free cash flow, 5 yr
- 64.8%
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $133.8M
- Total debt
- $2.1B
- Net debt
- $2.0B
- Debt/Equity
- 43.9x
- Debt/FCF
- 3.3x
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- -2.6%
Financials: ten years from the 10-Ks
Revenue
$1.4B
+28.5% a year over 9 years
FY2016FY2025
Margins
Operating33.6%Net22.7%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$644.6MOwner earnings$593.0M
FY2025
FY2016FY2025
Diluted shares
123.9M
-3.2% over 9 years, net buybacks
FY2016FY2025
Return on invested capital
15.5%
FY2025
FY2016FY2025
Net debt (below zero)
-$2.0B
$2.0B more debt than cash
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.0B | $1.4B |
| Revenue growth | 8.6% | 115.8% | -52.0% | 29.1% | 36.5% | 65.7% | 48.9% | 25.6% | 22.4% | 37.6% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net income | -$103.0M | $63.0M | -$80.3M | -$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| Net margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Diluted EPS | $-0.81 | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Return on invested capital? | – | – | – | – | 79.9% | – | 16.5% | 18.6% | 25.1% | 15.5% |
| Cash | ||||||||||
| Operating cash flow | -$50.4M | $134.1M | -$49.5M | -$85.4M | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M | $651.6M |
| Capital expenditure | $3.1M | $1.4M | $4.7M | $4.0M | $2.5M | $1.5M | $4.8M | $15.3M | $10.7M | $7.0M |
| Free cash flow | -$53.5M | $132.7M | -$54.2M | -$89.5M | $53.0M | $298.0M | $235.3M | $373.3M | $468.4M | $644.6M |
| Stock-based compensation | $25.6M | $30.7M | $35.7M | $34.8M | $17.2M | $20.8M | $24.4M | $36.6M | $43.4M | $51.6M |
| Owner earnings? | -$79.1M | $102.0M | -$89.9M | -$124.2M | $35.7M | $277.2M | $210.9M | $336.7M | $425.0M | $593.0M |
| Free cash flow per share | $-0.42 | $0.95 | $-0.38 | $-0.62 | $0.37 | $2.03 | $1.67 | $2.78 | $3.62 | $5.20 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | $0 | $0 | $200.0M | $150.1M | $350.1M | $200.0M | $402.4M | $250.0M | $342.4M |
| Diluted shares | 128.0M | 139.1M | 143.6M | 144.3M | 141.5M | 146.8M | 140.6M | 134.2M | 129.4M | 123.9M |
| Share count change? | 1.0% | 8.7% | 3.3% | 0.5% | -2.0% | 3.8% | -4.2% | -4.6% | -3.6% | -4.3% |
| Balance sheet | ||||||||||
| Cash and equivalents | $66.8M | $168.7M | $57.9M | $120.2M | $147.7M | $118.7M | $234.2M | $118.4M | $115.8M | $133.8M |
| Short-term investments | – | – | – | $301.1M | $220.3M | $622.2M | $128.6M | – | – | – |
| Total debt | $216.6M | $202.4M | $126.4M | $402.6M | $397.2M | $876.7M | $1.5B | $1.5B | $1.5B | $2.1B |
| Net debt | $149.9M | $33.6M | $68.4M | -$18.7M | $29.2M | $135.8M | $1.1B | $1.4B | $1.4B | $2.0B |
| Shareholders' equity | -$32.5M | $208.4M | $248.9M | $91.8M | $151.0M | $197.0M | $169.8M | $83.8M | $363.8M | $48.8M |
Latest filings
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Earnings release |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Earnings release |
| 2026-03-23 | DEF 14A | Proxy statement |
| 2026-02-17 | 10-K | Annual report |
| 2026-02-17 | 8-K | Earnings release |
| 2026-01-28 | 8-K | Earnings release |
| 2025-11-03 | 10-Q | Quarterly report |
| 2025-11-03 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
